WSNS Annual Meeting Announcement

Colleagues,

On behalf of the Board of the Washington State Neurological Society I would like to announce that this year’s Annual Meeting is being deferred.  It was the unanimous decision of the Board to not hold an in-person meeting this year due to the public health challenges posed by COVID-19.   We do anticipate that next year’s meeting will take place in October of 2021 and details will be forthcoming as this date draws closer.

In lieu of the Annual Meeting this year, the Board is planning some on-line events.  More details will be sent out in the next few months.

Finally, we would like to understand the impact that COVID-19 has had on your practice and how you care for patients.  A survey will be sent out to the membership to help gather data for us to better understand this and share with all of you.

Sincerely,

Michael A. Elliott, MD, FAAN
President, Washington State Neurological Society

Facebooktwittermail

Clinical Trial: Perampanel

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome.   ClinicalTrials.gov Identifier: NCT02834793

Inclusion Criteria:
•    Participants must have a diagnosis of Lennox-Gastaut Syndrome (LGS) as evidenced by:
•    more than one type of generalized seizure, including drop seizures (atonic, tonic, or myoclonic) for at least 6 months before Visit 1;
•    an EEG reporting diagnostic criteria for LGS at some point in their history (abnormal background activity accompanied by slow, spike, and wave pattern <2.5 Hz).
•    At least 2 years old at the time of consent.
•    Have been <11 years old at the onset of LGS.
•    At least 2 drop seizures per week in the 4-week Baseline Period preceding randomization.
•    Receiving 1 to 3 concomitant AEDs at a stable dose for at least 30 days before Visit 1 (vagal nerve stimulation (VNS) and ketogenic diet do not count as AEDs).

Exclusion Criteria:
•    Presence of progressive neurological disease
•    Presence of drop seizure clusters where individual seizures cannot be reliably counted (seizure clusters are defined as ≥2 drop seizures with <5 minutes between any 2 consecutive seizures)
•    Prior treatment with perampanel with discontinuation due to safety issues (related to perampanel)
•    Prior treatment with perampanel must have been discontinued at least 30 days before Visit 1
•    Evidence of clinically significant disease (eg, cardiac, respiratory, gastrointestinal, renal disease, hepatic disease) that in the opinion of the investigator(s) could affect the participant’s safety or study conduct
•    Scheduled for epilepsy-related surgery or any other form of surgery during the projected course of the study
•    Ketogenic diet and VNS, unless stable and ongoing, for at least 30 days before Visit 1

Location:
David Vossler, MD and Carole Burton RN, Rainier Clinical Research Center, Inc.
Renton, Washington, United States, 98057. Phone 1 425-251-1720

(Posted 10/06/16)

Facebooktwittermail